These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

710 related items for PubMed ID: 14983105

  • 1. How aggressive should initial therapy for rheumatoid arthritis be? Factors associated with response to 'non-aggressive' DMARD treatment and perspective from a 2-yr open label trial.
    Matteson EL, Weyand CM, Fulbright JW, Christianson TJ, McClelland RL, Goronzy JJ.
    Rheumatology (Oxford); 2004 May; 43(5):619-25. PubMed ID: 14983105
    [Abstract] [Full Text] [Related]

  • 2. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
    Hyrich KL, Watson KD, Silman AJ, Symmons DP, British Society for Rheumatology Biologics Register.
    Rheumatology (Oxford); 2006 Dec; 45(12):1558-65. PubMed ID: 16705046
    [Abstract] [Full Text] [Related]

  • 3. Triple therapy in early active rheumatoid arthritis: a randomized, single-blind, controlled trial comparing step-up and parallel treatment strategies.
    Saunders SA, Capell HA, Stirling A, Vallance R, Kincaid W, McMahon AD, Porter DR.
    Arthritis Rheum; 2008 May; 58(5):1310-7. PubMed ID: 18438851
    [Abstract] [Full Text] [Related]

  • 4. Prognostic factors in a large cohort of patients with early undifferentiated inflammatory arthritis after application of a structured management protocol.
    Quinn MA, Green MJ, Marzo-Ortega H, Proudman S, Karim Z, Wakefield RJ, Conaghan PG, Emery P.
    Arthritis Rheum; 2003 Nov; 48(11):3039-45. PubMed ID: 14613264
    [Abstract] [Full Text] [Related]

  • 5. Contemporary use of disease-modifying drugs in the management of patients with early rheumatoid arthritis in Norway.
    Nikolaisen C, Kvien TK, Mikkelsen K, Kaufmann C, Rødevand E, Nossent JC.
    Scand J Rheumatol; 2009 Nov; 38(4):240-5. PubMed ID: 19229766
    [Abstract] [Full Text] [Related]

  • 6. Efficacy of triple DMARD therapy in patients with RA with suboptimal response to methotrexate.
    O'Dell JR, Haire C, Erikson N, Drymalski W, Palmer W, Maloley P, Klassen LW, Wees S, Moore GF.
    J Rheumatol Suppl; 1996 Mar; 44():72-4. PubMed ID: 8833058
    [Abstract] [Full Text] [Related]

  • 7. Factors influencing length of time taking methotrexate in rheumatoid arthritis.
    Ortendahl M, Schettler JD, Fries JF.
    J Rheumatol; 2000 May; 27(5):1139-47. PubMed ID: 10813279
    [Abstract] [Full Text] [Related]

  • 8. Longterm combination therapy of refractory and destructive rheumatoid arthritis with methotrexate (MTX) and intramuscular gold or other disease modifying antirheumatic drugs compared to MTX monotherapy.
    Rau R, Schleusser B, Herborn G, Karger T.
    J Rheumatol; 1998 Aug; 25(8):1485-92. PubMed ID: 9712088
    [Abstract] [Full Text] [Related]

  • 9. Methotrexate, hydroxychloroquine, and intramuscular gold in rheumatoid arthritis: relative area under the curve effectiveness and sequence effects.
    Hurst S, Kallan MJ, Wolfe FJ, Fries JF, Albert DA.
    J Rheumatol; 2002 Aug; 29(8):1639-45. PubMed ID: 12180722
    [Abstract] [Full Text] [Related]

  • 10. [Comparison of efficacy and tolerability of triple combination therapy (methotrexate + sulfasalazine + hydroxychloroquine) with methotrexate monotherapy in patients with rheumatoid arthritis].
    Gubar' EE, Bochkova AG, Bunchuk NV.
    Ter Arkh; 2008 Aug; 80(5):25-30. PubMed ID: 18590110
    [Abstract] [Full Text] [Related]

  • 11. Response-driven combination therapy with conventional disease-modifying antirheumatic drugs can achieve high response rates in early rheumatoid arthritis with minimal glucocorticoid and nonsteroidal anti-inflammatory drug use.
    Proudman SM, Keen HI, Stamp LK, Lee AT, Goldblatt F, Ayres OC, Rischmueller M, James MJ, Hill CL, Caughey GE, Cleland LG.
    Semin Arthritis Rheum; 2007 Oct; 37(2):99-111. PubMed ID: 17391739
    [Abstract] [Full Text] [Related]

  • 12. The good initial response to therapy with a combination of traditional disease-modifying antirheumatic drugs is sustained over time: the eleven-year results of the Finnish rheumatoid arthritis combination therapy trial.
    Rantalaiho V, Korpela M, Hannonen P, Kautiainen H, Järvenpää S, Leirisalo-Repo M, Hakala M, Puolakka K, Julkunen H, Luosujärvi R, Möttönen T, FIN-RACo Trial Group.
    Arthritis Rheum; 2009 May; 60(5):1222-31. PubMed ID: 19404945
    [Abstract] [Full Text] [Related]

  • 13. Real-world effectiveness of select biologic and DMARD monotherapy and combination therapy in the treatment of rheumatoid arthritis: results from the RADIUS observational registry.
    Weaver AL, Lautzenheiser RL, Schiff MH, Gibofsky A, Perruquet JL, Luetkemeyer J, Paulus HE, Xia HA, Leff JA, RADIUS Investigators.
    Curr Med Res Opin; 2006 Jan; 22(1):185-98. PubMed ID: 16393444
    [Abstract] [Full Text] [Related]

  • 14. Treatment of rheumatoid arthritis with methotrexate and hydroxychloroquine, methotrexate and sulfasalazine, or a combination of the three medications: results of a two-year, randomized, double-blind, placebo-controlled trial.
    O'Dell JR, Leff R, Paulsen G, Haire C, Mallek J, Eckhoff PJ, Fernandez A, Blakely K, Wees S, Stoner J, Hadley S, Felt J, Palmer W, Waytz P, Churchill M, Klassen L, Moore G.
    Arthritis Rheum; 2002 May; 46(5):1164-70. PubMed ID: 12115219
    [Abstract] [Full Text] [Related]

  • 15. Treatment of early seropositive rheumatoid arthritis: doxycycline plus methotrexate versus methotrexate alone.
    O'Dell JR, Elliott JR, Mallek JA, Mikuls TR, Weaver CA, Glickstein S, Blakely KM, Hausch R, Leff RD.
    Arthritis Rheum; 2006 Feb; 54(2):621-7. PubMed ID: 16447240
    [Abstract] [Full Text] [Related]

  • 16. A good response to early DMARD treatment of patients with rheumatoid arthritis in the first year predicts remission during follow up.
    Verstappen SM, van Albada-Kuipers GA, Bijlsma JW, Blaauw AA, Schenk Y, Haanen HC, Jacobs JW, Utrecht Rheumatoid Arthritis Cohort Study Group (SRU).
    Ann Rheum Dis; 2005 Jan; 64(1):38-43. PubMed ID: 15130899
    [Abstract] [Full Text] [Related]

  • 17. Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial.
    Quinn MA, Conaghan PG, O'Connor PJ, Karim Z, Greenstein A, Brown A, Brown C, Fraser A, Jarret S, Emery P.
    Arthritis Rheum; 2005 Jan; 52(1):27-35. PubMed ID: 15641102
    [Abstract] [Full Text] [Related]

  • 18. Early suppression of disease activity is essential for maintenance of work capacity in patients with recent-onset rheumatoid arthritis: five-year experience from the FIN-RACo trial.
    Puolakka K, Kautiainen H, Möttönen T, Hannonen P, Korpela M, Hakala M, Järvinen P, Ahonen J, Forsberg S, Leirisalo-Repo M, FIN-RACo Trial Group.
    Arthritis Rheum; 2005 Jan; 52(1):36-41. PubMed ID: 15641055
    [Abstract] [Full Text] [Related]

  • 19. Impact of initial aggressive drug treatment with a combination of disease-modifying antirheumatic drugs on the development of work disability in early rheumatoid arthritis: a five-year randomized followup trial.
    Puolakka K, Kautiainen H, Möttönen T, Hannonen P, Korpela M, Julkunen H, Luukkainen R, Vuori K, Paimela L, Blåfield H, Hakala M, Leirisalo-Repo M.
    Arthritis Rheum; 2004 Jan; 50(1):55-62. PubMed ID: 14730599
    [Abstract] [Full Text] [Related]

  • 20. Rituximab therapy in patients with rheumatoid arthritis refractory or with contraindication to anti-tumour necrosis factor drugs: real-life experience in Finnish patients.
    Valleala H, Korpela M, Möttönen T, Hienonen-Kempas T, Kauppi M, Hannonen P, Leirisalo-Repo M.
    Scand J Rheumatol; 2009 Jan; 38(5):323-7. PubMed ID: 19585384
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 36.